LONDON--(BUSINESS WIRE)--Deep Knowledge Analytics, Big Innovation Centre and Innovation Eye launch'Artificial Intelligence in the UK: Industry landscape overview in 2021', the most comprehensive industry mapping made to date, profiling, categorising and analysing over 3,600 private and public sector entities across 20 sectors and 50 locations in the UK. The open-access report and IT platform, covers the latest developments in technology and innovation, best ranking companies and investors hubs, AI and COVID-19, policy and ethics, AI challenges and opportunities for the UK. Additionally, it profiles the top 100 UK AI experts and hubs, including think tanks, tech-hubs and doctoral training centres. The UK remains first in Europe and ranks third globally, behind the USA and China in developing AI technologies with a reported £9 billion investment growth for the industry between 2019 and 2021. The UK government continues to foster growth and industry development through initiatives in 5 key areas - human capital, lab to market developments, networking, regulation and infrastructure.

Neurotechnologies are based on the principles of the human nervous system and modeled on the human brain. NeuroTech can help researchers understand brain function and disfunction, and can help doctors treat neurological disorders. Some NeuroTech applications are focused on enhancing cognitive performance, improving sleep, and improving brain health for Longevity. Advances in AI could revolutionize NeuroTech over the next decade. NeuroTech has unprecedented prospects for growth both in terms of technology and as an industry.

Over the past 100 years the financial industry has largely excluded people in retirement. Even today tech entrepreneurs are ignoring financial inclusion for people over 60, who make up the wealthiest part of the financial system, and instead, are developing financial products for younger people. The most valuable and capable client demographic in terms of purchasing power are the citizens of the 7th Continent which is made up of 1 billion people over 60. The global spending power of this demographic is expected to be $15 trillion this year. Who will serve this market?

There's been significant growth in the AI for Drug Discovery sector this year. In the last quarter, the number of R&D centers increased by 5, companies increased by 20, collaborations increased by 30, and investors increased by 50. There are now 400 investors investing in AI for Drug Discovery including Google Ventures, Tencent, WuXi, Andreessen Horowitz, Khosla Ventures, and Sequoia Ventures. This week, Deep Knowledge Analytics Pharma Division published Landscape of AI for Drug Discovery and Advanced R&D Q2 2019. This report is the most comprehensive analytical report on the AI for Drug Discovery sector to date.

In our new book Longevity Industry 1.0 - Defining the Biggest and Most Complex Industry in Human History, Dmitry Kaminskiy and I distill the complex assembly of deep market intelligence and industry knowledge that we have developed over the past five years. We present the full-scope of the Global Longevity Industry showing exactly how we managed to define this complex and multidimensional industry and how we created a tangible framework for systematization and forecasting. This article includes the preface and the foreword from our book. Every cause of death is, in principle, preventable. I became aware of this in the 1990s and since then I have been following aging research very closely.

Deep Knowledge Ventures (DKV) is a Hong Kong based investment fund with teams in London, Geneva, and San Francisco. The fund primarily invests in DeepTech, AI, and advanced biomedicine. In 2015, DKV incorporated a subsidiary investment fund Deep Knowledge Life Sciences (DKLS), a London-based venture fund, focused on disruptive biopharmaceutical, medical device, and healthcare companies in a partnership with scientists at the universities of Oxford and Cambridge. DKLS it has been the lead investor so far in a number of promising biomedicine and longevity companies: Insilico Medicine (and the consortium of companies around Insilico Medicine, including Youth Laboratories and Longenesis) and other companies in the fields of Geroscience, NeuroTech, Preventive Medicine, AgeTech and Longevity. The Pharma Division of Deep Knowledge Analytics is the leading analytical entity of DKLS specifically focused on deep intelligence of the pharma industry and the AI for Drug Discovery sector. So far its reports have been covered by top-tier tech, business and finance media -- including Forbes, Financial Times, acknowledged by many other authoritative entities such as MIT Review -- and have been recognized by industry experts and executives as the dominant source of sophisticated industry analysis, pragmatic forecasting and tangible benchmarking on the AI in Pharma sector.

The many advances in deep learning reinforcement learning and generative adversarial learning made since 2014 are rapidly transforming multiple industries including search, translation, video games, retail, transportation, and many others. It is relatively easy to validate the performance of the AI systems in imaging, voice, text and other areas where human sensory systems can be used to rapidly verify the validity of the experimental results. However, in the pharmaceutical industry, the validation cycles take decades and cost billions of dollars. Most of the common questions asked by the pharmaceutical industry executives to all of the leading artificial intelligence groups worldwide deal with the novelty of the algorithms and experimental validation of the results in mice or even in humans. There is a grave disconnect between the leaders in AI focusing on the novelty of the algorithms and drug discovery and development experts focusing only on experimental data.

This is Pharma's AlphaGo moment when the potential for AI to radically transform the normal operating procedures and business models of the entire industry becomes tangibly obvious to the public. In the case of the AI industry, this happened in 2015, when AI company DeepMind succeeded in developing the first AI capable of beating a human Go champion in Go. This study by Insilico Medicine may be an analogous game-changing moment for Pharma. While it typically takes 2-3 years to go from initial drug discovery to preclinical validation, Insilico Medicine has done this in less than 2 months end-to-end. This is 15 times faster than Pharma companies capable of conducting the most efficient R&D processes. In a landmark study published in Nature Biotechnology on September 2, 2019, Insilico Medicine showed that they generated and validated a novel small molecule in just 46 days, and designed the drug from scratch based on specified molecular properties in just 21 days.